Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748759 | 1.00 | MAOB (0.74) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6522656 | 0.98 | MAOB (0.72) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5703124 | 0.98 | MAOB (0.72) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20148189 | 0.88 | POLB (0.68) | MAOBPOLBMEN1LMNAKMT2A | |
| SCHEMBL6742923 | 0.88 | POLB (0.68) | MAOBPOLBMEN1LMNAKMT2A | |
| SCHEMBL6742928 | 0.88 | POLB (0.68) | MAOBPOLBMEN1LMNAKMT2A | |
| SCHEMBL17574199 | 0.87 | MAOB (0.69) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19434678 | 0.85 | MAOB (0.67) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17561013 | 0.84 | MAOB (0.74) | MAOBPOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17561012 | 0.84 | MAOB (0.74) | MAOBPOLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | claimed |
| EP-3280405-A1 | INHIBITORS AND THEIR USES | Medical Research Council (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | claimed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| EP-2991968-B1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2021-11-10 | — | — | EP | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | disclosed |
| EP-3280405-A1 | INHIBITORS AND THEIR USES | Medical Research Council (GB) | 2018-02-14 | — | — | EP | disclosed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885POLB 3558/4885NPC1 2476/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | MAOB 1831/4885POLB 3872/4885NPC1 282/4885 |
| US-11154519-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885POLB 3558/4885NPC1 2476/4885 |
| US-11331286-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885POLB 3558/4885NPC1 2476/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | MAOB 1364/4885POLB 2406/4885NPC1 1533/4885 |
| US-11337941-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885POLB 3558/4885NPC1 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.